Virios Therapeutics (Virios Therapeutics) Total Current Liabilities : $0.57 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Virios Therapeutics Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Virios Therapeutics's total current liabilities for the quarter that ended in Mar. 2024 was $0.57

Virios Therapeutics Total Current Liabilities Historical Data

The historical data trend for Virios Therapeutics's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virios Therapeutics Total Current Liabilities Chart

Virios Therapeutics Annual Data

Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23

Total Current Liabilities

Get a 7-Day Free Trial 1.62 1.53 1.28 1.04 0.36

Virios Therapeutics Quarterly Data

Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24

Total Current Liabilities Get a 7-Day Free Trial 0.55 0.52 0.49 0.36 0.57

Virios Therapeutics Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Virios Therapeutics's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 0.359 + 0

+ Other Current Liabilities + Current Deferred Liabilities

= 0 + 0

= 0.36

Virios Therapeutics's Total Current Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 0.57 + 0

+ Other Current Liabilities + Current Deferred Liabilities

= 0 + 0

= 0.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Virios Therapeutics Total Current Liabilities Related Terms
Thank you for viewing the detailed overview of Virios Therapeutics's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Virios Therapeutics (Virios Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virios Therapeutics Inc (NAS:VIRI) » Definitions » Total Current Liabilities

Comparable Companies

BRTX INTI BCEL ENZN ITRM BNTC ARAV OGEN VYNE ONVO OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX

Traded in Other Exchanges

N/A

Address

44 Milton Avenue, Alpharetta, GA, USA, 30009

Website

https://www.virios.com

Virios Therapeutics Inc is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia. The company is engaged in the development of its product, IMC-1, for people who are suffering from fibromyalgia.

Executives

William Pridgen director 44 MILTON AVENUE, ALPHARETTA GA 30009

Gregory Scott Duncan director, officer: Chief Executive Officer 44 MILTON AVENUE, ALPHARETTA GA 30009

Richard James Whitley director UAB, CHB 303, 1600 7TH AVENUE SOUTH, BIRMINGHAM AL 35233-1711

Angela Walsh officer: VP of Finance 44 MILTON AVENUE, ALPHARETTA GA 30009

De La Rosa Abel director 44 MILTON AVENUE, ALPHARETTA GA 30009

John C Thomas director 8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615

David R Keefer director 44 MILTON AVENUE, ALPHARETTA GA 30009

Ralph Grosswald officer: Vice President of Operations 44 MILTON AVENUE, ALPHARETTA GA 30009

Roger Michael Gendreau officer: Chief Medical Officer 44 MILTON AVENUE, ALPHARETTA GA 30009

Richard Alan Burch director 44 MILTON AVENUE, ALPHARETTA GA 30009

Virios Therapeutics (Virios Therapeutics) Headlines

From GuruFocus

Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
By sperokesalga sperokesalga • 05-04-2023

Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
By Marketwired • 08-10-2023

Virios Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update
By Business Wire Business Wire • 05-12-2022

Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023
By Marketwired • 11-06-2023

Virios Therapeutics Announces Initial FDA Feedback on Proposed IMC-1 Phase 3 Program for Treatment of Fibromyalgia
By sperokesalga sperokesalga • 04-24-2023

Virios Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on Thursday, May 12, 2022
By Business Wire Business Wire • 05-05-2022

Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
By sperokesalga sperokesalga • 05-25-2023

Virios Therapeutics Announces�Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study
By Marketwired • 07-17-2023

Virios Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update
By Business Wire Business Wire • 11-14-2022

Virios Therapeutics Announces Halt to At-The-Market Offering Sales
By Marketwired • 08-14-2023

Virios Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Current Liabilities	Get a 7-Day Free Trial															0.55	0.52	0.49	0.36	0.57

Total Current Liabilities	=	Accounts Payable & Accrued Expense	+	Short-Term Debt & Capital Lease Obligation
	=	0.359	+	0
	+	Other Current Liabilities	+	Current Deferred Liabilities
	=	0	+	0
	=	0.36

William Pridgen	director	44 MILTON AVENUE, ALPHARETTA GA 30009
Gregory Scott Duncan	director, officer: Chief Executive Officer	44 MILTON AVENUE, ALPHARETTA GA 30009
Richard James Whitley	director	UAB, CHB 303, 1600 7TH AVENUE SOUTH, BIRMINGHAM AL 35233-1711
Angela Walsh	officer: VP of Finance	44 MILTON AVENUE, ALPHARETTA GA 30009
De La Rosa Abel	director	44 MILTON AVENUE, ALPHARETTA GA 30009
John C Thomas	director	8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615
David R Keefer	director	44 MILTON AVENUE, ALPHARETTA GA 30009
Ralph Grosswald	officer: Vice President of Operations	44 MILTON AVENUE, ALPHARETTA GA 30009
Roger Michael Gendreau	officer: Chief Medical Officer	44 MILTON AVENUE, ALPHARETTA GA 30009
Richard Alan Burch	director	44 MILTON AVENUE, ALPHARETTA GA 30009